PTC Therapeutics reports Q2 revenue of $361M, raises 2026 guidance on Sephience momentum

Filed July 30, 2026 · Period ending July 28, 2026 · ~2 min read

Key Changes

• high

  Q2 2026 total revenue reached $361M with product revenue of $239M, more than doubling year-over-year; company swung to net income of $83.5M from a $64.8M loss in Q2 2025, driven by commercial portfolio strength.

  Exhibit 99.1 view on EDGAR →
• high

  Sephience generated $151M in Q2 revenue, up 21% sequentially from Q1, with 1,647 patients on commercial therapy globally as of June 30; full-year product revenue guidance raised to $850-950M from prior $750-850M range.

  Exhibit 99.1 view on EDGAR →
• medium

  PTC received a $50M milestone payment from Novartis upon dosing the first patient in the INVEST-HD Phase 3 study of votoplam for Huntington's disease; Novartis is conducting and funding the trial targeting ~770 participants.

  Exhibit 99.1 view on EDGAR →